Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroid osteoporosis

I R Reid1, A B Grey

  • 1City Hospital, Aberdeen, UK.

Bailliere'S Clinical Rheumatology
|October 1, 1993
PubMed
Summary
This summary is machine-generated.

Glucocorticoids cause osteoporosis by inhibiting bone formation, leading to significant bone mass reduction. Early intervention with hormone replacement, calcium, and potentially bisphosphonates or vitamin D can mitigate bone loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

Expert opinion on drug safety·2022
Same author

Bone-friendly lifestyle and the role of calcium or vitamin D supplementation.

Climacteric : the journal of the International Menopause Society·2021
Same author

Publisher Correction to: Development of the Asia Pacific Consortium on Osteoporosis (APCO) framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Management of Paget's disease of bone.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Journal of internal medicine·2019
Same journal

Regional soft tissue pains: alias myofascial pain?

Bailliere's clinical rheumatology·1999
Same journal

The knee

Bailliere's clinical rheumatology·1999
Same journal

The elbow, forearm, wrist and hand

Bailliere's clinical rheumatology·1999
Same journal

Shoulder disorders: a state-of-the-art review

Bailliere's clinical rheumatology·1999
Same journal

The neck

Bailliere's clinical rheumatology·1999
Same journal

Treatment options for regional musculoskeletal pain: what is the evidence?

Bailliere's clinical rheumatology·1999
See all related articles

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoids are potent medications with significant side effects.
  • Osteoporosis is a major concern in patients on long-term glucocorticoid therapy.
  • Glucocorticoid-induced osteoporosis (GIOP) is characterized by reduced bone formation and increased fracture risk.

Purpose of the Study:

  • To outline the mechanisms of glucocorticoid-induced bone loss.
  • To provide recommendations for managing and preventing osteoporosis in patients receiving glucocorticoids.
  • To highlight therapeutic options for mitigating bone density reduction.

Main Methods:

  • Review of existing literature on glucocorticoid effects on bone.
  • Analysis of bone loss mechanisms and contributing factors.

Related Experiment Videos

  • Evaluation of current treatment strategies for GIOP.

    • Main Results:

    • Glucocorticoids inhibit bone formation, causing 10-20% bone mass reduction at measured sites and 30-40% in trabecular bone.
    • Dosage and duration of steroid treatment correlate with bone loss extent.
    • Other predictive factors for bone loss are not identified.

    Conclusions:

    • Sex hormone replacement and calcium optimization are recommended for patients with deficiency.
    • Bisphosphonates, calcitonin, fluoride, or vitamin D metabolites may be added for severe or persistent bone loss.
    • Annual bone density monitoring is advised until stabilization, with thiazide diuretics as a potential adjunct therapy.